• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

firstwordpharmaJuly 06, 2021

Tag: NPPA , Ibuprofen , ranitidine , carbamazepine

India’s pharmaceutical pricing regulator has allowed a one-time price hike of 50% for ibuprofen, ranitidine and carbamazepine, Business Standard reported.

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

After the latest increase, the price of carbamazepine, a drug used to treat epilepsy, would range from Rs 1 to Rs 4.61 per tablet. The new price of ranitidine, an antacid, would be in the range of Rs 1 to Rs 2.43 per tablet or per ml of liquid, while the price of ibuprofen, an analgesic, would be 59 paise to Rs 1.04 per tablet.

The National Pharmaceutical Pricing Authority (NPPA) allowed the price hike during its meeting held on June 28.


Previous:Oncodesign Appoints Aline Aubertin as an Independent Director of the Board of Directors

Next:France's Sanofi expects Covid vaccine to be ready by December

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Ranitidine Hydrochloride

Ranitidine Hydrochloride
Ranitidine   HCl Tablets

Ranitidine   HCl Tablets
IBUPROFEN LYSINE

IBUPROFEN LYSINE
Ibuprofen EP Impurity E

Ibuprofen EP Impurity E
Ibuprofen

Ibuprofen
Ibuprofen EP Impurity I

Ibuprofen EP Impurity I
Carbamazepine

Carbamazepine
Ibuprofen tablet

Ibuprofen tablet
carbamazepine

carbamazepine
Ibuprofen EP Impurity C

Ibuprofen EP Impurity C

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service